Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Licensing
-
By Donald Zuhn — On Tuesday, GTC Biotherapeutics, Inc. announced that it had been granted a non-exclusive worldwide license from stART Licensing, Inc. to use stART’s nuclear transfer patents and patent applications to produce therapeutic proteins in the milk of transgenic animals. GTC Biotherapeutics, Inc. commercializes therapeutic proteins through transgenic animal technology. GTC’s…
-
By Mark Chael — As we reported previously, Eli Lilly & Co. had been in the process of acquiring Hypnion, Inc. and its pipeline of insomnia drug candidates. On Tuesday, Lilly announced that it had completed the acquisition, which has been valued at around $315 million. With this acquisition, Lilly enhances its drug…
-
By Jason Derry — On Wednesday, Roche announced that it would acquire BioVeris Corporation for about $600 million. The purchase of BioVeris will allow Roche to expand its immunochemistry business into the life science research and development, drug discovery, and clinical research areas. Roche’s announcement that it would be acquiring BioVeris came two…
-
By Donald Zuhn — On Wednesday, Cell Signaling Technology, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for its application entitled "Immunoaffinity Isolation of Modified Peptides from Complex Mixtures." A search of Public PAIR indicates that U.S. Application No. 10/175,486 will issue as Patent No.…
-
By Christopher P. Singer — MedImmune and sanofi pasteur announced today that they have entered into a licensing agreement concerning certain of MedImmune’s intellectual property relating to virus generation. Specifically, sanofi pasteur has licensed MedImmune’s "reverse genetics" technology which provides the ability to make viruses from DNA segments. Sanofi pasteur intends to use…
-
By Jason Derry — Sanofi-Aventis and Oxford BioMedica have announced an agreement under which the two companies will jointly develop and market TroVax® for treating and preventing cancer. TroVax® is a gene-based therapeutic cancer vaccine, and is currently in Phase III clinical trials as a treatment for renal cancer. Under the terms of…
-
Windhover Information Inc. will be holding the 14th Annual Euro-Biotech Forum 2007 on June 26-28, 2007 in Paris, France. According to Windhover, Euro-Biotech offers European and American life sciences companies an opportunity to network with hundreds of potential pharmaceutical and biotech partners, with one to one meetings between Forum participants being scheduled using Windhover's partnering…
-
By Donald Zuhn — Oxford BioMedica announced on March 12th that it has entered into an agreement to acquire Oxxon Therapeutics Ltd. The transaction – valued at about US $31 million – will be completed, in part, by the issuance of more than 27 million Oxford BioMedica shares to Oxxon shareholders. Oxford BioMedica…
-
By Jason Derry — Abbott Laboratories has announced that it will no longer launch new medicines in Thailand. In addition, Abbott has decided to withdraw its current applications for medicines in Thailand. The decision is based on Thailand’s recent decision to issue compulsory licenses for Abbott’s AIDS drug Kaletra, and the failure to…
-
By Donald Zuhn — Schering-Plough Corporation announced on March 12th that its Board of Directors has approved the purchase of Organon BioSciences N.V. from Akzo Nobel N.V. for US $14.4 billion. Schering-Plough chairman and CEO Fred Hassan noted that the acquisition would give Schering-Plough immediate access to central nervous system and women’s health…
Patent Docs 